Praxis Precision Medicines, Inc. (PRAX)
351.81
-3.34
(-0.94%)
USD |
NASDAQ |
Sep 04, 16:00
352.32
+0.51
(+0.14%)
After-Hours: 20:00
Praxis Precision Medicines Research and Development Expense (Quarterly) : 69.42M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 69.42M |
| March 31, 2026 | 77.99M |
| December 31, 2025 | 77.51M |
| September 30, 2025 | 65.80M |
| June 30, 2025 | 63.01M |
| March 31, 2025 | 60.81M |
| December 31, 2024 | 56.29M |
| September 30, 2024 | 41.88M |
| June 30, 2024 | 27.26M |
| March 31, 2024 | 26.98M |
| December 31, 2023 | 18.39M |
| September 30, 2023 | 17.26M |
| June 30, 2023 | 25.61M |
| March 31, 2023 | 25.50M |
| Date | Value |
|---|---|
| December 31, 2022 | 28.33M |
| September 30, 2022 | 30.44M |
| June 30, 2022 | 43.62M |
| March 31, 2022 | 52.65M |
| December 31, 2021 | 43.51M |
| September 30, 2021 | 33.14M |
| June 30, 2021 | 25.68M |
| March 31, 2021 | 17.93M |
| December 31, 2020 | 16.27M |
| September 30, 2020 | 12.79M |
| June 30, 2020 | 9.05M |
| March 31, 2020 | 6.868M |
| December 31, 2019 | 5.699M |
| September 30, 2019 | 9.346M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Insmed, Inc. | 210.03M |
| Perspective Therapeutics, Inc. | 20.40M |
| Vertex Pharmaceuticals, Inc. | 993.80M |
| AbbVie, Inc. | 2.344B |
| TG Therapeutics, Inc. | 95.34M |